{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:09:03Z","timestamp":1780445343607,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00393-023-01345-2","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T10:02:26Z","timestamp":1682503346000},"page":"307-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Eosinophilie: hypereosinophiles Syndrom versus eosinophile Granulomatose mit Polyangiitis","Eosinophilia: hypereosinophilic syndrome vs. eosinophilic granulomatosis with polyangiitis"],"prefix":"10.1007","volume":"82","author":[{"given":"Julia U.","family":"Holle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Moosig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"issue":"3","key":"1345_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","volume":"130","author":"P Valent","year":"2012","unstructured":"Valent\u00a0P, Klion\u00a0AD, Horny\u00a0HP, Roufosse\u00a0F, Gotlib\u00a0J, Weller\u00a0PF et\u00a0al (2012) Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J\u00a0Allergy Clin Immunol 130(3):607\u201312.e9","journal-title":"J Allergy Clin Immunol"},{"issue":"20","key":"1345_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber\u00a0DA, Orazi\u00a0A, Hasserjian\u00a0R, Thiele\u00a0J, Borowitz\u00a0MJ, Le Beau\u00a0MM et\u00a0al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"1","key":"1345_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/all.15544","volume":"78","author":"P Valent","year":"2023","unstructured":"Valent\u00a0P, Klion\u00a0AD, Roufosse\u00a0F, Simon\u00a0D, Metzgeroth\u00a0G, Leiferman\u00a0KM et\u00a0al (2023) Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes. Allergy 78(1):47\u201359. https:\/\/doi.org\/10.1111\/all.15544","journal-title":"Allergy"},{"issue":"1","key":"1345_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.26352","volume":"97","author":"W Shomali","year":"2022","unstructured":"Shomali\u00a0W, Gotlib\u00a0J (2022) World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(1):129\u2013148","journal-title":"Am J Hematol"},{"issue":"1","key":"1345_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette\u00a0JC, Falk\u00a0RJ, Bacon\u00a0PA, Basu\u00a0N, Cid\u00a0MC, Ferrario\u00a0F et\u00a0al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65(1):1\u201311","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1345_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/art.1780370206","volume":"37","author":"JC Jennette","year":"1994","unstructured":"Jennette\u00a0JC, Falk\u00a0RJ, Andrassy\u00a0K, Bacon\u00a0PA, Churg\u00a0J, Gross\u00a0WL et\u00a0al (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37(2):187\u2013192","journal-title":"Arthritis Rheum"},{"issue":"3","key":"1345_CR7","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/art.41982","volume":"74","author":"PC Grayson","year":"2022","unstructured":"Grayson\u00a0PC, Ponte\u00a0C, Suppiah\u00a0R, Robson\u00a0JC, Craven\u00a0A, Judge\u00a0A et\u00a0al (2022) 2022 American college of rheumatology\/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheumatol 74(3):386\u2013392","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1345_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00005792-198403000-00001","volume":"63","author":"JG Lanham","year":"1984","unstructured":"Lanham\u00a0JG, Elkon\u00a0KB, Pusey\u00a0CD, Hughes\u00a0GR (1984) Systemic vasculitis with asthma and eosinophilia: a\u00a0clinical approach to the Churg-Strauss syndrome. Medicine 63(2):65\u201381","journal-title":"Medicine"},{"issue":"1","key":"1345_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.autrev.2016.09.018","volume":"16","author":"V Cottin","year":"2017","unstructured":"Cottin\u00a0V, Bel\u00a0E, Bottero\u00a0P, Dalhoff\u00a0K, Humbert\u00a0M, Lazor\u00a0R et al (2017) Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): a study of 157\u00a0patients by the groupe d\u2019etudes et de recherche sur les maladies orphelines pulmonaires and the European respiratory society taskforce on eosinophilic granulomatosis with polyangiitis (Churg-strauss). Autoimmun Rev 16(1):1\u20139","journal-title":"Autoimmun Rev"},{"key":"1345_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25906","author":"GJ Ruan","year":"2020","unstructured":"Ruan\u00a0GJ, Smith\u00a0CJ, Day\u00a0C, Harmsen\u00a0WS, Zblewski\u00a0DL, Alkhateeb\u00a0H et al (2020) A population-based study of chronic eosinophilic leukemia-not otherwise specified in the United States. Am J Hematol. https:\/\/doi.org\/10.1002\/ajh.25906","journal-title":"Am J Hematol"},{"issue":"4","key":"1345_CR11","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/iid3.495","volume":"9","author":"G Requena","year":"2021","unstructured":"Requena\u00a0G, Logie\u00a0J, Gibbons\u00a0DC, Steinfeld\u00a0J, Van Dyke\u00a0MK (2021) The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom. Immun Inflamm Dis 9(4):1447\u20131451","journal-title":"Immun Inflamm Dis"},{"issue":"1","key":"1345_CR12","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jaci.2010.03.035","volume":"126","author":"MM Crane","year":"2010","unstructured":"Crane\u00a0MM, Chang\u00a0CM, Kobayashi\u00a0MG, Weller\u00a0PF (2010) Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J\u00a0Allergy Clin Immunol 126(1):179\u2013181","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"1345_CR13","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","volume":"126","author":"AD Klion","year":"2015","unstructured":"Klion\u00a0AD (2015) How I treat hypereosinophilic syndromes. Blood 126(9):1069\u20131077","journal-title":"Blood"},{"issue":"6","key":"1345_CR14","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","volume":"124","author":"PU Ogbogu","year":"2009","unstructured":"Ogbogu\u00a0PU, Bochner\u00a0BS, Butterfield\u00a0JH, Gleich\u00a0GJ, Huss-Marp\u00a0J, Kahn\u00a0JE et al (2009) Hypereosinophilic syndrome: a\u00a0multicenter, retrospective analysis of clinical characteristics and response to therapy. J\u00a0Allergy Clin Immunol 124(6):1319\u201325.e3","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1345_CR15","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","volume":"104","author":"A Pardanani","year":"2004","unstructured":"Pardanani\u00a0A, Brockman\u00a0SR, Paternoster\u00a0SF, Flynn\u00a0HC, Ketterling\u00a0RP, Lasho\u00a0TL et al (2004) FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89\u00a0consecutive patients with moderate to severe eosinophilia. Blood 104(10):3038\u20133045","journal-title":"Blood"},{"key":"1345_CR16","doi-asserted-by":"publisher","first-page":"100809","DOI":"10.1016\/j.blre.2021.100809","volume":"49","author":"G Helbig","year":"2021","unstructured":"Helbig\u00a0G, Klion\u00a0AD (2021) Hypereosinophilic syndromes\u2014an enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment. Blood Rev 49:100809","journal-title":"Blood Rev"},{"issue":"5","key":"1345_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","volume":"92","author":"F Legrand","year":"2013","unstructured":"Legrand\u00a0F, Renneville\u00a0A, MacIntyre\u00a0E, Mastrilli\u00a0S, Ackermann\u00a0F, Cayuela\u00a0JM et al (2013) The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a\u00a0survey of 44 cases. Medicine 92(5):e1\u2013e9","journal-title":"Medicine"},{"issue":"2","key":"1345_CR18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hon.919","volume":"28","author":"G Helbig","year":"2010","unstructured":"Helbig\u00a0G, Moskwa\u00a0A, Hus\u00a0M, Piszcz\u00a0J, Swiderska\u00a0A, Urbanowicz\u00a0A et al (2010) Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript\u2014results of Polish multicentre study. Hematol Oncol 28(2):93\u201397","journal-title":"Hematol Oncol"},{"issue":"6","key":"1345_CR19","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/all.12843","volume":"71","author":"P Khoury","year":"2016","unstructured":"Khoury\u00a0P, Desmond\u00a0R, Pabon\u00a0A, Holland-Thomas\u00a0N, Ware\u00a0JM, Arthur\u00a0DC et al (2016) Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. Allergy 71(6):803\u2013810","journal-title":"Allergy"},{"issue":"1","key":"1345_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1600-0609.2012.01799.x","volume":"89","author":"M Arefi","year":"2012","unstructured":"Arefi\u00a0M, Garcia\u00a0JL, Penarrubia\u00a0MJ, Queizan\u00a0JA, Hermosin\u00a0L, Lopez-Corral\u00a0L et al (2012) Incidence and clinical characteristics of myeloproliferative neoplasms displaying a\u00a0PDGFRB rearrangement. Eur J Haematol 89(1):37\u201341","journal-title":"Eur J Haematol"},{"issue":"9","key":"1345_CR21","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00277-017-3067-x","volume":"96","author":"M Jawhar","year":"2017","unstructured":"Jawhar\u00a0M, Naumann\u00a0N, Schwaab\u00a0J, Baurmann\u00a0H, Casper\u00a0J, Dang\u00a0TA et\u00a0al (2017) Imatinib in myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol 96(9):1463\u20131470","journal-title":"Ann Hematol"},{"issue":"5","key":"1345_CR22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/j.1365-2141.2006.06038.x","volume":"133","author":"A Tefferi","year":"2006","unstructured":"Tefferi\u00a0A, Patnaik\u00a0MM, Pardanani\u00a0A (2006) Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 133(5):468\u2013492","journal-title":"Br J Haematol"},{"issue":"2","key":"1345_CR23","first-page":"277","volume":"27","author":"J Churg","year":"1951","unstructured":"Churg\u00a0J, Strauss\u00a0L (1951) Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 27(2):277\u2013301","journal-title":"Am J Pathol"},{"issue":"9","key":"1345_CR24","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.3390\/jcm11092573","volume":"11","author":"R Redondo-Rodriguez","year":"2022","unstructured":"Redondo-Rodriguez\u00a0R, Mena-Vazquez\u00a0N, Cabezas-Lucena\u00a0AM, Manrique-Arija\u00a0S, Mucientes\u00a0A, Fernandez-Nebro\u00a0A (2022) Systematic review and metaanalysis of worldwide incidence and prevalence of antineutrophil cytoplasmic antibody (ANCA) associated vasculitis. J\u00a0Clin Med 11(9):2573. https:\/\/doi.org\/10.3390\/jcm11092573","journal-title":"J Clin Med"},{"issue":"6","key":"1345_CR25","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","volume":"72","author":"F Moosig","year":"2013","unstructured":"Moosig\u00a0F, Bremer\u00a0JP, Hellmich\u00a0B, Holle\u00a0JU, Holl-Ulrich\u00a0K, Laudien\u00a0M et al (2013) A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150\u00a0patients. Ann Rheum Dis 72(6):1011\u20131017","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1345_CR26","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/00005792-199601000-00003","volume":"75","author":"L Guillevin","year":"1996","unstructured":"Guillevin\u00a0L, Lhote\u00a0F, Gayraud\u00a0M, Cohen\u00a0P, Jarrousse\u00a0B, Lortholary\u00a0O et al (1996) Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342\u00a0patients. Medicine 75(1):17\u201328","journal-title":"Medicine"},{"issue":"9","key":"1345_CR27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.7326\/0003-4819-143-9-200511010-00006","volume":"143","author":"R Sable-Fourtassou","year":"2005","unstructured":"Sable-Fourtassou\u00a0R, Cohen\u00a0P, Mahr\u00a0A, Pagnoux\u00a0C, Mouthon\u00a0L, Jayne\u00a0D et al (2005) Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 143(9):632\u2013638","journal-title":"Ann Intern Med"},{"issue":"9","key":"1345_CR28","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/art.21250","volume":"52","author":"RA Sinico","year":"2005","unstructured":"Sinico\u00a0RA, Di Toma\u00a0L, Maggiore\u00a0U, Bottero\u00a0P, Radice\u00a0A, Tosoni\u00a0C et al (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52(9):2926\u20132935","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1345_CR29","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","volume":"10","author":"PA Lyons","year":"2019","unstructured":"Lyons\u00a0PA, Peters\u00a0JE, Alberici\u00a0F, Liley\u00a0J, Coulson\u00a0RMR, Astle\u00a0W et al (2019) Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun 10(1):5120","journal-title":"Nat Commun"},{"issue":"3","key":"1345_CR30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1056\/NEJMoa1108735","volume":"367","author":"PA Lyons","year":"2012","unstructured":"Lyons\u00a0PA, Rayner\u00a0TF, Trivedi\u00a0S, Holle\u00a0JU, Watts\u00a0RA, Jayne\u00a0DR et al (2012) Genetically distinct subsets within ANCA-associated vasculitis. N\u00a0Engl J Med 367(3):214\u2013223","journal-title":"N Engl J Med"},{"issue":"8","key":"1345_CR31","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung\u00a0SA, Langford\u00a0CA, Maz\u00a0M, Abril\u00a0A, Gorelik\u00a0M, Guyatt\u00a0G et al (2021) 2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 73(8):1366\u20131383","journal-title":"Arthritis Rheumatol"},{"key":"1345_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223764","author":"B Hellmich","year":"2023","unstructured":"Hellmich B, Sanchez-Alamo B, Schirmer JH et al (2023) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Diseas. https:\/\/doi.org\/10.1136\/ard-2022-223764","journal-title":"Ann Rheum Diseas"},{"issue":"3","key":"1345_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00393-017-0394-1","volume":"76","author":"JH Schirmer","year":"2017","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, de Groot\u00a0K, Hellmich\u00a0B, Holle\u00a0JU, Kneitz\u00a0C et al (2017) S1 guidelines diagnostics and treatment of ANCA-associated vasculitis. Z\u00a0Rheumatol 76(3):77\u2013104","journal-title":"Z Rheumatol"},{"key":"1345_CR34","doi-asserted-by":"crossref","first-page":"abstract L21","DOI":"10.1002\/art.41556","volume":"73","author":"B Terrier","year":"2021","unstructured":"Terrier\u00a0B, Pugnet\u00a0G, de Moreuil\u00a0C, Bonnotte\u00a0B, Benhamou\u00a0Y, Diot\u00a0E et al (2021) Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: a\u00a0double-blind, randomized, controlled trial (abstract). Arthritis Rheumatol 73:abstract L21","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"1345_CR35","doi-asserted-by":"publisher","first-page":"e0185880","DOI":"10.1371\/journal.pone.0185880","volume":"12","author":"F Maritati","year":"2017","unstructured":"Maritati\u00a0F, Alberici\u00a0F, Oliva\u00a0E, Urban\u00a0ML, Palmisano\u00a0A, Santarsia\u00a0F et al (2017) Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial. PLoS ONE 12(10):e185880","journal-title":"PLoS ONE"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-023-01345-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01345-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T13:46:18Z","timestamp":1702302378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-023-01345-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["1345"],"URL":"https:\/\/doi.org\/10.1007\/s00393-023-01345-2","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"28 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>J.U.\u00a0Holle<\/b>: A.\u00a0Finanzielle Interessen: J.\u00a0Holle gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Niedergelassener Internist\/Rheumatologe | Mitgliedschaften: DGRh, DGIM, EUVAS, BDRh, Rheuma-Liga. <b>F.\u00a0Moosig<\/b>: A.\u00a0Finanzielle Interessen: F.\u00a0Moosig gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Facharzt f\u00fcr Innere Medizin\/Rheumatologie, Kuhberg\u00a05a\u20137, 24534 Neum\u00fcnster.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}